Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX)

CUSIP: 74365A309

Q3 2024 13F Holders as of 30 Sep 2024

Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
80,165,500
Total 13F shares
3,383,529
Share change
-2,087,873
Total reported value
$3,451,053
Put/Call ratio
59%
Price per share
$1.02
Number of holders
43
Value change
-$2,253,845
Number of buys
10
Number of sells
46

Quarterly Holders Quick Answers

What is CUSIP 74365A309?
CUSIP 74365A309 identifies PLX - Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) as of Q3 2024

As of 30 Sep 2024, Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) was held by 43 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,383,529 shares. The largest 10 holders included RENAISSANCE TECHNOLOGIES LLC, GSA CAPITAL PARTNERS LLP, MILLENNIUM MANAGEMENT LLC, Stratos Wealth Partners, LTD., BRIDGEWAY CAPITAL MANAGEMENT, LLC, BlackRock, Inc., CITADEL ADVISORS LLC, Orin Green Financial, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and Squarepoint Ops LLC. This page lists 44 institutional shareholders reporting positions in this security for the Q3 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.